|
1
|
Sauter ER, Herlyn M, Liu SC, Litwin S and
Ridge JA: Prolonged response to antisense cyclin D1 in a human
squamous cancer xenograft model. Clin Cancer Res. 6:654–660.
2000.PubMed/NCBI
|
|
2
|
Trakatelli M, Ulrich C, del Marmol V,
Euvrard S, Stockfleth E and Abeni D: Epidemiology of nonmelanoma
skin cancer (NMSC) in Europe: Accurate and comparable data are
needed for effective public health monitoring and interventions. Br
J Dermatol. 156 Suppl 3:S1–S7. 2007. View Article : Google Scholar
|
|
3
|
Karia PS, Han J and Schmults CD: Cutaneous
squamous cell carcinoma: Estimated incidence of disease, nodal
metastasis, and deaths from disease in the United States, 2012. J
Am Acad Dermatol. 68:957–966. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Dong JT: Anticancer activities of PPARγ in
breast cancer are context-dependent. Am J Pathol. 182:1972–1975.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Issemann I and Green S: Activation of a
member of the steroid hormone receptor superfamily by peroxisome
proliferators. Nature. 347:645–650. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kersten S, Desvergne B and Wahli W: Roles
of PPARs in health and disease. Nature. 405:421–424. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Elstner E, Müller C, Koshizuka K,
Williamson EA, Park D, Asou H, Shintaku P, Said JW, Heber D and
Koeffler HP: Ligands for peroxisome proliferator-activated
receptorgamma and retinoic acid receptor inhibit growth and induce
apoptosis of human breast cancer cells in vitro and in BNX mice.
Proc Natl Acad Sci USA. 95:8806–8811. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sarraf P, Mueller E, Jones D, King FJ,
DeAngelo DJ, Partridge JB, Holden SA, Chen LB, Singer S, Fletcher C
and Spiegelman BM: Differentiation and reversal of malignant
changes in colon cancer through PPARgamma. Nat Med. 4:1046–1052.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Motomura W, Okumura T, Takahashi N, Obara
T and Kohgo Y: Activation of peroxisome proliferator-activated
receptor gamma by troglitazone inhibits cell growth through the
increase of p27KiP1 in human. Pancreatic carcinoma cells. Cancer
Res. 60:5558–5564. 2000.PubMed/NCBI
|
|
10
|
Inoue K, Kawahito Y, Tsubouchi Y, Kohno M,
Yoshimura R, Yoshikawa T and Sano H: Expression of peroxisome
proliferator-activated receptor gamma in renal cell carcinoma and
growth inhibition by its agonists. Biochem Biophys Res Commun.
287:727–732. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Nicol CJ, Yoon M, Ward JM, Yamashita M,
Fukamachi K, Peters JM and Gonzalez FJ: PPARgamma influences
susceptibility to DMBA-induced mammary, ovarian and skin
carcinogenesis. Carcinogenesis. 25:1747–1755. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mao-Qiang M, Fowler AJ, Schmuth M, Lau P,
Chang S, Brown BE, Moser AH, Michalik L, Desvergne B, Wahli W, et
al: Peroxisome-proliferator-activated receptor (PPAR)-gamma
activation stimulates keratinocyte differentiation. J Invest
Dermatol. 123:305–312. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kundoor V, Zhang X, Bommareddy A, Khalifa
S, Fahmy H and Dwivedi C: Chemopreventive effects of sarcotriol on
ultraviolet B-induced skin tumor development in SKH-1 hairless
mice. Mar Drugs. 5:197–207. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sarfaraz S, Adhami VM, Syed DN, Afaq F and
Mukhtar H: Cannabinoids for cancer treatment: Progress and promise.
Cancer Res. 68:339–342. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
He G, Thuillier P and Fischer SM:
Troglitazone inhibits cyclin D1 expression and cell cycling
independently of PPARgamma in normal mouse skin keratinocytes. J
Invest Dermatol. 123:1110–1119. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chen Z, He P, Ding X, Huang Y, Gu H and Ni
X: PPARγ stimulates expression of L-type amino acid and taurine
transporters in human placentas: The evidence of PPARγ regulating
fetal growth. Sci Rep. 5:126502015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wu M, Melichian DS, Chang E,
Warner-Blankenship M, Ghosh AK and Varga J: Rosiglitazone abrogates
bleomycin-induced scleroderma and blocks profibrotic responses
through peroxisome proliferator-activated receptor-gamma. Am J
Pathol. 174:519–533. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Mueller E, Sarraf P, Tontonoz P, Evans RM,
Martin KJ, Zhang M, Fletcher C, Singer S and Spiegelman BM:
Terminal differentiation of human breast cancer through PPAR gamma.
Mol Cell. 1:465–470. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Jiang WG, Redfern A, Bryce RP and Mansel
RE: Peroxisome proliferator activated receptor-gamma (PPAR-gamma)
mediates the action of gamma linolenic acid in breast cancer cells.
Prostaglandins Leukot Essent Fatty Acids. 62:119–127. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Youssef J and Badr M: Peroxisome
proliferator-activated receptors and cancer: Challenges and
opportunities. Br J Pharmacol. 164:68–82. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kitamura S, Miyazaki Y, Shinomura Y, Kondo
S, Kanayama S and Matsuzawa Y: Peroxisome proliferator-activated
receptor gamma induces growth arrest and differentiation markers of
human colon cancer cells. Jpn J Cancer Res. 90:75–80. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tsujie M, Nakamori S, Okami J, Hayashi N,
Hiraoka N, Nagano H, Dono K, Umeshita K, Sakon M and Monden M:
Thiazolidinediones inhibit growth of gastrointestinal, biliary, and
pancreatic adenocarcinoma cells through activation of the
peroxisome proliferator-activated receptor gamma/retinoid X
receptor alpha pathway. Exp Cell Res. 289:143–151. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Itami A, Watanabe G, Shimada Y, Hashimoto
Y, Kawamura J, Kato M, Hosotani R and Imamura M: Ligands for
peroxisome proliferator-activated receptor gamma inhibit growth of
pancreatic cancers both in vitro and in vivo. Int J Cancer.
94:370–376. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kawa S, Nikaido T, Unno H, Usuda N,
Nakayama K and Kiyosawa K: Growth inhibition and differentiation of
pancreatic cancer cell lines by PPAR gamma ligand troglitazone.
Pancreas. 24:1–7. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Altiok S, Xu M and Spiegelman BM:
PPARgamma induces cell cycle withdrawal: Inhibition of E2F/DP
DNA-binding activity via down-regulation of PP2A. Genes Dev.
11:1987–1998. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ramachandran L, Manu KA, Shanmugam MK, Li
F, Siveen KS, Vali S, Kapoor S, Abbasi T, Surana R, Smoot DT, et
al: Isorhamnetin inhibits proliferation and invasion and induces
apoptosis through the modulation of peroxisome
proliferator-activated receptor γ activation pathway in gastric
cancer. J Biol Chem. 287:38028–38040. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lee NJ, Oh JH, Ban JO, Shim JH, Lee HP,
Jung JK, Ahn BW, Yoon DY, Han SB, Ham YW and Hong JT:
4-O-methylhonokiol, a PPARγ agonist, inhibits prostate tumour
growth: p21-mediated suppression of NF-κB activity. Br J Pharmacol.
168:1133–1145. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang S, Awad KS, Elinoff JM, Dougherty EJ,
Ferreyra GA, Wang JY, Cai R, Sun J, Ptasinska A and Danner RL: G
protein-coupled receptor 40 (GPR40) and peroxisome
proliferator-activated receptor γ (PPARγ): AN integrated
two-receptor signaling pathway. J Biol Chem. 290:19544–19557. 2015.
View Article : Google Scholar : PubMed/NCBI
|
